Status:
UNKNOWN
Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?
Lead Sponsor:
Far Eastern Memorial Hospital
Conditions:
Peritoneal Dialysis
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Hyperphosphatemia is frequently seen in patients with end-stage renal disease (ESRD). Hyperphosphatemia usually results in a high calcium-phosphorus product (CPP) which may subsequently lead to artery...
Detailed Description
OBJECTIVES The purpose of this study is to determine if long-term use of alendronate can suppress coronary artery and aortic calcification in chronic PD patients. The effect of alendronate on bone min...
Eligibility Criteria
Inclusion
- receive maintenance peritoneal dialysis for more than 3 months
- have high calcium-phosphate product (\>55 (mg/dL)2)
- have chest X-ray proven aortic calcification or coronary artery calcification proven by coronary angiography
Exclusion
- had been hospitalized in recent 3 months due to severe comorbid disease
- hypersensitive to alendronate or any of its components
- have esophageal disease
- not able to stand or sit upright for 30 minutes
- have refractory hypocalcemia
- being pregnant
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00299572
Start Date
March 1 2006
End Date
December 1 2006
Last Update
March 7 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Far Eastern Memorial Hospital
Taipei, Taiwan, 220